All Stories

  1. Toward Small-Molecule Inhibition of Protein–Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions

    Article • Current Topics in Medicinal Chemistry, July 2018, Bentham Science Publishers

    Dr Peter Buchwald

  2. Fully Automated Islet Cell Counter (ICC) for the Assessment of Islet Mass, Purity, and Size Distribution by Digital Image Analysis

    Article • Cell Transplantation, October 2016, SAGE Publications

    Dr Peter Buchwald

  3. TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation

    Article • Current Drug Targets, April 2015, Bentham Science Publishers

    Dr Peter Buchwald

  4. Small‐molecule modulators of the OX40–OX40 ligand co‐stimulatory protein–protein interaction

    Article • British Journal of Pharmacology, October 2014, Wiley

    Dr Allison L Bayer, Dr Peter Buchwald

  5. Effects of representative glucocorticoids on TNFα- and CD40L-induced NF-κB activation in sensor cells

    Article • Steroids, July 2014, Elsevier

    Dr Peter Buchwald

  6. Bilinear Model for the Size‐Dependency of the CYP3A4 Inhibitory Activity of Structurally Diverse Compounds

    Article • Molecular Informatics, December 2013, Wiley

    Dr Peter Buchwald

  7. The promiscuous protein binding ability of erythrosine B studied by metachromasy (metachromasia)

    Article • Journal of Molecular Recognition, March 2013, Wiley

    Dr Peter Buchwald

  8. Retrometabolic Drug Design and Targeting

    Article • October 2012, Wiley

    Dr Peter Buchwald

  9. Retrometabolism‐Based Drug Design and Targeting

    Article • April 2010, Wiley

    Dr Peter Buchwald

  10. Glucocorticoid receptor binding: A biphasic dependence on molecular size as revealed by the bilinear LinBiExp model

    Article • Steroids, February 2008, Elsevier

    Dr Peter Buchwald

  11. Retrometabolic drug design: Principles and recent developments

    Article • Pure and Applied Chemistry, January 2008, De Gruyter

    Dr Peter Buchwald

  12. Computer-aided retrometabolic drug design: soft drugs

    Article • Expert Opinion on Drug Discovery, July 2007, Informa Healthcare

    Dr Peter Buchwald

  13. A general bilinear model to describe growth or decline time profiles

    Article • Mathematical Biosciences, January 2007, Elsevier

    Dr Peter Buchwald

  14. Targeting of Neuropharmaceuticals by Chemical Delivery Systems

    Article • February 2006, Wiley

    Dr Peter Buchwald

  15. General Linearized Biexponential Model for QSAR Data Showing Bilinear-Type Distribution

    Article • Journal of Pharmaceutical Sciences, November 2005, Elsevier

    Dr Peter Buchwald

  16. Designing Safer (Soft) Drugs by Avoiding the Formation of Toxic and Oxidative Metabolites

    Article • Molecular Biotechnology, January 2004, Springer Science + Business Media

    Dr Peter Buchwald

  17. Retrometabolism‐Based Drug Design and Targeting

    Article • January 2003, Wiley

    Dr Peter Buchwald

  18. Brain-Targeted Drug Delivery

    Article • American Journal of Drug Delivery, January 2003, Springer Science + Business Media

    Dr Peter Buchwald

  19. Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease

    Article • Drug Discovery Today, July 2002, Elsevier

    Dr Peter Buchwald

  20. Structure-Metabolism Relationships Steric Effects and the Enzymatic Hydrolysis of Carboxylic Esters

    Article • Mini-Reviews in Medicinal Chemistry, May 2001, Bentham Science Publishers

    Dr Peter Buchwald

  21. ChemInform Abstract: Soft Drug Design: General Principles and Recent Applications

    Article • ChemInform, March 2000, Wiley

    Dr Peter Buchwald

  22. Soft drug design: General principles and recent applications

    Article • Medicinal Research Reviews, January 2000, Wiley

    Dr Peter Buchwald

  23. Soft drug design: General principles and recent applications

    Article • Medicinal Research Reviews, January 2000, Wiley

    Dr Peter Buchwald

  24. Drug targeting via retrometabolic approaches

    Article • Pharmacology & Therapeutics, October 1997, Elsevier

    Dr Peter Buchwald

  25. Designing Safer (Soft) Drugs by Avoiding the Formation of Toxic and Oxidative Metabolites

    Article • Springer Science + Business Media

    Dr Peter Buchwald